Associated Papers
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.
Thavaneswaran S et al.
Npj Precision Oncology, 2024
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Ishiyama N et al.
Cancer Research, 2023
35503682 (PubMed )
Supplement: can-21-0940_supplementary_data_suppsd.docx
Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer.
Rack S et al.
Cancers, 2022
35267442 (PubMed )
Supplement: cancers-14-01133-s001.zip › cancers-1574535-supplementary.xlsx › Supp_Table_2_-_Variants
Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms.
Braunstein EM et al.
Cancers, 2021
34209587 (PubMed )
Supplement: cancers-13-03246-s001.zip › cancers-1247417-supplementary.xlsx › Table_S7
The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.
Jacob SL et al.
Heliyon, 2020
32420470 (PubMed )
Supplement: mmc1.pdf
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW et al.
Biomolecules, 2019
Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma.
Yeon Yeon S et al.
Pathology, Research and Practice, 2019
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.
Loree JM et al.
Journal of the National Cancer Institute, 2018
High accuracy mutation detection in leukemia on a selected panel of cancer genes.
Kalender Atak Z et al.
Plos One, 2012
22675565 (PubMed )
Supplement: pone.0038463.s007.xlsx › TableS3
Select a paper to view details